Advaxis News Releases

Date	Title and Summary	Additional Formats
November 19, 2021	Advaxis, Inc. Issues Letter to Stockholders Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposals MONMOUTH JUNCTION, N.J. , Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the	PDF Version
November 18, 2021	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Proposed Merger with Biosight Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals MONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today	PDF Version
November 4, 2021	Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to build long term stockholder value	PDF Version
November 3, 2021	OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeriamonocytogenes)
November 3, 2021	Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced that leading proxy advisory firm Institutional Shareholder Services Inc.	PDF Version
October 22, 2021	OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
September 10, 2021	Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of ADXS-504 for the treatment of early prostate cancer ADXS-503 Phase 1/2 data presented at ASCO	PDF Version
August 11, 2021	Nasdaq Grants Advaxis, Inc. an Extension to November 22, 2021, to Regain Compliance with the $1.00 Minimum Bid Price Rule and Complete Merger Transaction with Biosight, Ltd. MONMOUTH JUNCTION, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter	PDF Version
July 15, 2021	Advaxis Announces Initiation of Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer Study in biochemically recurrent prostate cancer expands off-the-shelf ADXS-HOT program to second indication MONMOUTH JUNCTION, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of	PDF Version
July 14, 2021	Advaxis to Present at the Non-Small Cell Lung Cancer Drug Development Summit PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Andres Gutierrez, M.D., Executive Vice President and Chief Medical Officer	PDF Version